• Ensysce Biosciences initiated the final stage of its PF614-MPAR-102 clinical study, enrolling the first patient to evaluate MPAR overdose-protection technology.
• Earlier clinical data have already been presented, showing the drug maintained therapeutic exposure at prescribed use while limiting exposure under excessive oral dosing.
• The final-stage readout is expected in the future, aiming to confirm the protective effect across a broader set of dosing scenarios.
• Program positioning centers on an opioid designed to curb overdose risk without relying on traditional abuse-deterrent approaches, supporting a potential differentiated safety label.
• The study is supported by the National Institute on Drug Abuse, which could reduce development cost and bolster external validation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief on June 26, 2026, and is solely responsible for the information contained therein.